Clinical applications of anti-CD20 antibodies
- 1 November 1999
- journal article
- review article
- Published by Elsevier BV in Journal of Laboratory and Clinical Medicine
- Vol. 134 (5), 445-450
- https://doi.org/10.1016/s0022-2143(99)90164-6
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Apoptosis of Malignant Human B Cells by Ligation of CD20 With Monoclonal AntibodiesBlood, 1998
- THE POTENTIAL FOR IMMUNOCONJUGATES IN LYMPHOMA THERAPYHematology/Oncology Clinics of North America, 1997
- Chimeric Anti-CD20 (IDEC-C2B8) Monoclonal Antibody Sensitizes a B Cell Lymphoma Cell Line to Cell Killing by Cytotoxic DrugsCancer Biotherapy & Radiopharmaceuticals, 1997
- Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphomaBlood, 1994
- CD20: a regulator of cell-cycle progression of B lymphocytesImmunology Today, 1994
- Retention of B-cell-specific monoclonal antibodies by human lymphoma cellsBlood, 1994
- Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20Blood, 1994
- Analysis of two cDNA clones encoding the B lymphocyte antigen CD20 (B1, Bp35), a type III integral membrane protein.The Journal of Experimental Medicine, 1988
- Isolation and structure of a cDNA encoding the B1 (CD20) cell-surface antigen of human B lymphocytes.Proceedings of the National Academy of Sciences of the United States of America, 1988
- Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomasBlood, 1987